ArticleEuropean thyroid journal2026
Predictors of retreatment after radiofrequency ablation of benign thyroid nodules: role of pre-treatment growth rate and viable volume.
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiofrequency ablation (RFA) has emerged as a minimally invasive and effective alternative to surgery for benign thyroid nodules, providing a significant volume reduction and symptom relief. However, approximately one in five patients experiences regrowth requiring retreatment. This study aimed to identify robust predictive factors - spanning the pre-, peri-, and post-treatment periods - to guide patient selection and follow-up strategies. Methods: In this retrospective cohort study, 293 patients underwent RFA for benign thyroid nodules at Pitié-Salpêtrière Hospital between 2018 and 2023. Retreatment, defined as a second RFA within five years, was the primary outcome. Twelve clinical and treatment variables were analyzed using univariate and multivariate logistic regression. Predictive performance was assessed with receiver operating characteristic (ROC) curves and corresponding area under the curve (AUC) values. Results: Sixty-one patients (20.8%) required retreatment. Among twelve parameters from three periods (pre-treatment, peri-treatment, and post-treatment), optimal multivariate models identified six significant ones. The pre-treatment growth rate (AUC = 0.808, OR = 1.505, 95% CI: 1.182-1.952, P < 0.001) and six-month viable volume (AUC = 0.886, OR = 1.252, 95% CI: 1.088-1.496, P < 0.001) showed the highest predictive accuracy. Optimal thresholds were 1.75 mm/year for pre-treatment growth rate and 4.45 mL for viable volume. Patients with viable volume ≤ 2.1 mL had a <5% risk of retreatment, compared to >70% when viable volume exceeded 18.05 mL. Four predictive abacuses were developed to facilitate clinical application. Conclusion: Pre-treatment growth rate and six-month viable volume are strong, independent predictors of retreatment after RFA of benign thyroid nodules. Incorporating these parameters into clinical decision-making may enhance patient selection, tailor treatment intensity, and inform follow-up intervals, thereby reducing the risk of retreatment and improving cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.